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Abstract
Limited information exists on the performance of antigen-based rapid inﬂuenza diagnostic tests (RIDT) in diagnosing the novel inﬂuenza
A pandemic (H1N1) 2009 virus. Large studies evaluating these tests in consecutive patients with a broad clinical spectrum of inﬂuenza-
like illnesses are needed. We assessed the ClearView Exact Inﬂuenza A & B test (Inverness Medical, Cologne, Germany) in compari-
son with real-time (r)RT-PCR for detection of the novel inﬂuenza A (H1N1) in a population-based prospective study of 1016 adults and
children with suspected inﬂuenza in Spain. Three hundred and one (29.6%) patients had a positive sample with the rRT-PCR assay for
inﬂuenza A and B viruses, with 297 (29.2%) conﬁrmed cases of the novel inﬂuenza A pandemic (H1N1) 2009 virus. Fifty (16.8%) patients
with conﬁrmed A (H1N1) 2009 virus were admitted to hospital, with six of them to the intensive care unit. In comparison with rRT-
PCR, the ClearView Exact Inﬂuenza A & B test had a sensitivity of 19% (95% CI 14–23), a speciﬁcity of 100%, a positive predictive
value of 100%, and a negative predictive value of 75% (95% CI 72–78). The sensitivity of the test remained low across all demographic
and clinical strata. Although a positive RIDT performed well in predicting PCR-conﬁrmed infection with pandemic H1N1 virus, the sen-
sitivity was very low and a negative test result was a poor predictor of the absence of infection.
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Introduction
Rapid antigen-based inﬂuenza diagnostic tests (RIDTs) may
provide clinically meaningful information in patients with sus-
pected seasonal inﬂuenza [1]. These tests might be particu-
larly valuable in the setting of the current inﬂuenza pandemic
for clinical and public health purposes, facilitating the prompt
implementation of antiviral therapy and control measures.
Limited information exists on the performance of RIDTs in
diagnosing the novel inﬂuenza A pandemic (H1N1) 2009
virus. Preliminary studies have reported sensitivities in the
range 10–69% [2–7]. Most of these studies evaluated the tests
using stored specimens that had previously tested positive for
novel inﬂuenza A (H1N1) virus and some of them were
limited by the small number of positive samples and the
reduced composition of the cohort. To more accurately
determine the performance of these tests, clinical studies that
include a consecutive series of patients with a broad clinical
spectrum of inﬂuenza-like illnesses should be conducted.
The present study aimed to evaluate a RIDT for detection
of novel inﬂuenza A (H1N1) virus in a population-based pro-
spective study of adults and children with suspected inﬂuenza
in Spain.
Materials and Methods
From 15 July until November 20, 2009, all suspected cases of
novel inﬂuenza A (H1N1) virus infection cared for in two
health care institutions serving a population of 475 000 people
in Alicante, Spain, were included in the investigation. At both
sites, two foam swabs supplied with the test kit were used to
collect oropharyngeal and nasopharyngeal swab samples from
each patient with inﬂuenza-like illness and were placed in the
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same standard sterile viral transport media (Vircell, Granada,
Spain or Copan Diagnostics Inc., Brescia, Italy) and then
refrigerated and tested within 4–48 h. In the ﬁrst 94 patients
cared for in one of the sites (Hospital General Universitario
de Elche), additional (oropharyngeal and nasopharyngeal)
swabs were collected and RIDT performed immediately by
attending clinicians at the point of care. All samples were col-
lected as per standard of care for routine diagnostic testing
and informed consent was therefore not required.
Rapid antigen-based inﬂuenza diagnostic tests
Antigen-based rapid tests were performed using the Clear-
view Exact Inﬂuenza A & B test (Inverness Medical,
Cologne, Germany), an immunochromatographic membrane
assay that utilizes sandwich immunoassay technology for the
detection of inﬂuenza A and B viral antigens. The test con-
sists of a dipstick device containing a membrane strip that
has separate regions with immobilized inﬂuenza A and B spe-
ciﬁc monoclonal antibodies and a coloured gold conjugate
that also consists of speciﬁc inﬂuenza A and B antibodies.
The assay was performed in accordance with the manufac-
turer’s instructions. The accuracy of the test was determined
using real-time (r)RT-PCR as reference standard.
rRT-PCR
Nucleic acids were extracted with the MagNA Pure Compact
instrument (Roche Applied Science, Mannheim, Germany)
with Nucleic Acid Isolation Kit I. Brieﬂy, a 400-lL respiratory
specimen volume was used for extraction without a prior
centrifugation step, and an elution volume of 50 lL was
selected. Two rRT-PCR assays were performed for inﬂuenza
A and B viruses and for inﬂuenza A subtype conﬁrmation. The
ﬁrst rRT-PCR was performed with the artus Inﬂuenza LC
rRT-PCR kit (Qiagen, Hilden, Germany), a ready-to-use sys-
tem for the detection of inﬂuenza virus speciﬁc RNA using
PCR in the LightCycler instrument and the reagent manufac-
turer’s recommended cycling parameters. A second rRT-PCR
was performed on inﬂuenza A/B positive samples with the
RealTime ready Inﬂuenza A/H1N1 Detection Set (Roche
Applied Science). The kit contains pre-mixed primers and
hydrolysis probes for detection of inﬂuenza A matrix protein
2 and hemagglutinin H1 (Mexico) genes. All tests were per-
formed in accordance with the manufacturer’s instructions.
Results
The main demographic characteristics of the patients are
shown in Table 1. There were 527 (51.9%) men and 489
(48.1%) women, with a median age of 45 years (range
3 months to 97 years). Three hundred and one (29.6%)
patients had a positive sample with the rRT-PCR assay for inﬂu-
enza A and B viruses, with 297 (29.2%) conﬁrmed as cases of
the novel inﬂuenza A pandemic (H1N1) 2009 virus. The major-
ity of such patients were young adults (75% of them £50 years
of age). Fifty (16.8%) patients with conﬁrmed A (H1N1) 2009
virus were admitted to hospital, with six of them to the inten-
sive care unit. Other characteristics of patients with novel inﬂu-
enza A pandemic (H1N1) 2009 virus are detailed in Table 1.
The Clearview Exact Inﬂuenza A & B test was performed
for 995 (97.9%) of 1016 samples. The test was not performed
for 21 (2.1%) patients: 17 patients in the rRT-PCR negative
group and four patients in the rRT-PCR positive group. The
accuracy of the test according to patient characteristics and
whether it was performed at the bedside by attending clini-
cians or in the laboratory is shown in Table 2. The RIDT
result was positive for 55 patients. No false positive results
were found. Overall, the test had a sensitivity of 19% (95% CI
14–23), a speciﬁcity of 100%, a positive predictive value of
100%, and a negative predictive value of 75% (95% CI 72–78).
The sensitivity of the RIDT remained low across all demo-
graphic and clinical groups and did not vary substantially
regardless of whether the RIDT was performed immediately
after collection by attending clinicians or whether the sam-
ples were placed in viral transport media and performed in
the laboratory (Table 2).
Discussion
The present study shows that rapid point-of-care testing
with the Clearview Exact Inﬂuenza A & B test allows an
TABLE 1. Baseline characteristics of patients with suspected
inﬂuenza and cases of novel inﬂuenza A (H1N1) conﬁrmed









assay (n = 297)
Age (years), median (range) 45 (0–97) 27.6 (1–79)
Distribution of cases by age group (years)
0–14 154 (15.2) 68 (22.9)
15–24 100 (9.8) 57 (19.2)
25–44 230 (22.6) 88 (29.6)
‡45 500 (49.2) 71 (23.9)
Males 527 (51.9) 129 (43.4)
Females 489 (48.1) 168 (56.6)
Pregnant women 21 (2.1) 7 (2.4)
Clinical presentation
Inﬂuenza-like illness 893 (87.9) 287 (96.6)
Pneumonia 123 (12.1) 10 (3.4)
Site of management
Outpatients 686 (67.5) 247 (83.2)
Admitted to hospital 330 (32.5) 50 (16.8)
Data are number of cases (%), unless otherwise indicated.
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accurate rapid diagnosis of infection with the novel inﬂu-
enza A (H1N1) virus only in a small proportion of cases.
When compared with standard rRT-PCR, the test had
very low sensitivity. By contrast, the speciﬁcity was very
high. The interpretation of the predictive values found
should take into consideration that, when the study was
conducted, the novel inﬂuenza A pandemic (H1N1) 2009
was the predominant circulating virus in the community
and that one-third of the patients tested by rRT-PCR had
inﬂuenza.
This is the ﬁrst large prospective cohort study evaluating
a RIDT in patients with suspected inﬂuenza during the cur-
rent pandemic with the novel inﬂuenza A (H1N1) 2009 virus.
The study is population-based and beneﬁts from the consec-
utive recruitment of patients with a broad spectrum of dis-
ease, including subjects of different ages and with a different
severity of disease.
Because we used a speciﬁc commercial kit, it can be
argued that the results may not be generalized to other
RIDT. However, the low sensitivity of RIDT found in the
present clinical study is supported by recent reports suggest-
ing the low analytical sensitivity of these assays on cultured
pandemic (H1N1) virus [8,9] and on clinical material analysed
by using two different RIDTs, virus culture and a Luminex-
based multiplex assay [3]. The results obtained in the
present study are also in line with a recent report by
Drexler et al. [5] from Germany in which only 11% of 144
PCR-positive frozen clinical specimens were positive when
tested retrospectively with the Binax NOW Inﬂuenza A & B
test (Inverness Medical), comprising a commercial kit similar
to the one we used [5]. The accuracy observed in our
cohort study is also in agreement with the performance of
RIDT reported by Uyeki et al. [10] when testing persons
with inﬂuenza-like illness at three separate study sites in the
USA during the 2007–2008 inﬂuenza seasons.
The sensitivity of RIDT for detection of the novel inﬂu-
enza A (H1N1) virus found in the present study is lower
than that reported in preliminary studies from the USA
[2,4]. Faix et al. [2] tested military personnel in San Diego,
California, with the QuickVue Inﬂuenza A + B (Quidel Corp.,
San Diego, CA, USA) and found a positive RIDT for 20 of 39
patients who had positive results by RT-PCR (sensitivity
51%). The CDC conducted an initial evaluation of three RID-
Ts on a state health laboratories collection of 45 specimens
that were positive for the novel inﬂuenza A (H1N1) 2009
virus by rRT-PCR and found a sensitivity of 40–69% [4].
The sensitivity of RIDT to detect the novel inﬂuenza A
(H1N1) virus may depend on the viral load in respiratory
specimens [4,5], which is potentially affected by the severity
of disease, type of specimen, and timing of collection, trans-
portation and storage of the specimen before testing. In
addition, age may also be an important factor because chil-
dren generally shed more virus for longer periods compared
to adults. The differences in sensitivity among studies should
be interpreted in the light of these factors. Selection bias
might have led to an over-representation of samples from
patients more likely to be positive with RIDT in previous
retrospective analyses of stored specimens. In the present
study, the sensitivity of the RIDT remained low across all
demographic and clinical groups, including children and
patients admitted to hospital where the sensitivity was <25%.
Unfortunately, information on viral load and the timing of
the specimen collection relating to clinical symptoms initia-
tion was not available for analysis.
Optimizing specimen collection and testing immediately
after collection is expected to increase the likelihood of
detecting inﬂuenza virus with RIDTs and other diagnostic
tests. It was disappointing, however, that sensitivity remained
low in the present study when the RIDT was performed
immediately after collection by attending clinicians.
TABLE 2. Accuracy of the rapid
inﬂuenza diagnostic test (RIDT)
according to patient characteristics















0–14 24 (13–34) 100 100 62 (54–70)
15–24 23 (12–34) 100 100 49 (39–60)
25–44 23 (14–31) 100 100 68 (61–74)
‡45 8 (2–15) 100 100 87 (84–90)
Male gender 19 (12–25) 100 100 79 (76–83)
Female gender 18 (13–24) 100 100 70 (66–74)
Clinical presentation
Inﬂuenza-like illness 16 (11–20) 100 100 71 (68–75)
Pneumonia 10 (0–29) 100 100 93 (88–97)
Outpatients 18 (13–23) 100 100 68 (65–72)
Patients admitted to hospital 22 (11–33) 100 100 88 (84–91)
RIDT performed immediately
by the clinicians at point of care
11 (3–19) 100 100 45 (35–56)
RIDT performed at the Laboratory 20 (15–25) 100 100 78 (75–81)
Overall 19 (14–23) 100 100 75 (72–78)
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Of note was the high speciﬁcity and positive predictive
value of the test. This is in agreement with the preliminary
observations of Faix et al. [2], and indicates that a positive
RIDT result can be safely used for clinical and public health
decision-making. Nonetheless, it is worth noting that RIDT
cannot differentiate among inﬂuenza A virus subtypes. There-
fore, the test cannot distinguish inﬂuenza infections caused by
novel inﬂuenza A virus versus seasonal inﬂuenza A viruses.
The present study provides timely information on the per-
formance of the RIDT for diagnosis of the current inﬂuenza
pandemic that may be of interest for clinicians and public
health workers. Unfortunately, the test assessed in this
investigation had low sensitivity for the detection of the
novel inﬂuenza A pandemic (H1N1) 2009 virus in a real clini-
cal setting. A negative RIDT result is a poor predictor of the
absence of infection with this virus. Conversely, when the
novel inﬂuenza A pandemic (H1N1) 2009 virus is circulating
in the community, as occurred in the present study, a posi-
tive RIDT indicates that this virus is likely to be present.
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